InterPAD - DETAILS

etoposide, VePesid, 33419-42-0, Toposar, trans-Etoposide, (-)-Etoposide, Lastet, Zuyeyidal, Etoposidum, Etoposido, Etoposidum [INN-Latin], VP-16, Etoposide (VP16), VP 16 (pharmaceutical), Sintopozid, Vepesid J, VP-16-213, VP 16-213, Etoposido [INN-Spanish], 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside, NK 171, CCRIS 2392, NSC-141540, DTXSID5023035, HSDB 6517, UNII-6PLQ3CP4P3, EINECS 251-509-1, 6PLQ3CP4P3, 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), EPEG, CHEBI:4911, Epipodophyllotoxin VP-16213, Etoposide (VP-16), VP 16, 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin, CHEMBL44657, Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside), Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-, Eposide, DTXCID601473876, Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside, 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside), NSC 141540, Etoposide [USAN:USP:INN:BAN:JAN], Etosid, ETOPOSIDE (IARC), ETOPOSIDE [IARC], Etoposidum (INN-Latin), Etoposido (INN-Spanish), ETOPOSIDE (MART.), ETOPOSIDE [MART.], ETOPOSIDE (USP-RS), ETOPOSIDE [USP-RS], (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, Etopophos (phosphate salt), ETOPOSIDE (EP IMPURITY), ETOPOSIDE [EP IMPURITY], ETOPOSIDE (EP MONOGRAPH), ETOPOSIDE (USP IMPURITY), ETOPOSIDE [EP MONOGRAPH], ETOPOSIDE [USP IMPURITY], ETOPOSIDE (USP MONOGRAPH), ETOPOSIDE [USP MONOGRAPH], Etopol, Prestwick 211, Demethylepipodophyllotoxin-beta-D-ethylideneglucoside, VP 16213, MFCD00869325, NSC141540, Etoposide (USAN:USP:INN:BAN:JAN), (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one, 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one, SMR000112002, VePESID (TN), 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside, Demethyl Epipodophyllotoxin Ethylidine Glucoside, Etoposide,(S), NCGC00016821-01, (5R,5aR,8aR,9S)-9-(((4aR,6R,7R,8R,8aS)-7,8-Dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, EVP, Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-, CAS-33419-42-0, Etoposide; VP-16, CPD000112002, ETOPOSIDE [INN], ETOPOSIDE [JAN], ETOPOSIDE [MI], ETOPOSIDE [HSDB], ETOPOSIDE [USAN], Prestwick3_000396, ETOPOSIDE [VANDF], 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside, ETOPOSIDE [WHO-DD], ETOPOSIDE [WHO-IP], SCHEMBL4259, BSPBio_000611, 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-, 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4- hydroxy-3,4-dimethyloxyphenyl)furo (3',4'':6,7) naptho-(2,3-d)-1,3-dioxol-6 (5aH)-one, MLS000049957, MLS001074951, MLS001424283, MLS002153463, MLS002207239, MLS002222184, Etoposide (JP17/USP/INN), BPBio1_000673, GTPL6815, ETOPOSIDE [ORANGE BOOK], L01CB01, ETOPOSIDUM [WHO-IP LATIN], HMS2052N05, HMS2089F14, HMS2096O13, HMS2232L03, HMS3713O13, (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, EPE, EX-A1207, Tox21_110630, Tox21_302201, BDBM50127140, s1225, Etoposide - CAS 33419-42-0, AKOS007930275, BCP9000669, CCG-101165, CS-1774, DB00773, Etoposide, synthetic, >=98%, powder, NC00415, SDCCGSBI-0050405.P002, 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside, NCGC00179504-02, NCGC00255126-01, AS-35312, BE164434, Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-, Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one-, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl), (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-, HY-13629, ETOPOSIDE IMPURITY C (EP IMPURITY), SBI-0051910.P002, AB00438905, FT-0630571, NS00009585, EN300-97099, C01576, D00125, AB00438905-17, AB00438905-18, AB00438905_19, Q418817, SR-01000763196, SR-01000763196-3, BRD-K37798499-001-02-5, BRD-K37798499-001-05-8, BRD-K37798499-001-10-8, BRD-K37798499-001-14-0, BRD-K37798499-001-27-2, -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, Etoposide, British Pharmacopoeia (BP) Reference Standard, Z1304065033, Etoposide, European Pharmacopoeia (EP) Reference Standard, Etoposide, United States Pharmacopeia (USP) Reference Standard, 4''-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE), Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard, (5R,5AR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahy, (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one, (5R,5AR,8AR,9S)-9-((4,6-O-((1R)-ETHANE-1,1-DIYL)-.ALPHA.-D-GLUCOPYRANOSYL)OXY)-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDRO(2)BENZOFURO(5,6-F)(1,3)BENZODIOXOL-6(5AH)-ONE, (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[5,6-f][1,3]benzodioxol-8-one, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3'',4'':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, 121471-01-0, 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3'',4'''':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one, FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE-, 9-((4,6-O-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSYL)OXY)5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL), (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))-

No.	Title	Href
1	Chemosensitizing Effect of Saikosaponin B on B16F10 Melanoma Cells. Nutr Cancer. 2017 Apr;69(3):505-511. doi: 10.1080/01635581.2017.1285407.	`Click`
2	The role of oxidative stress in the cooperation of parthenolide and etoposide in HL-60 cells. Folia Med Cracov. 2020;60(4):5-17.	`Click`
3	Methylselenocysteine Potentiates Etoposide-Induced Cytotoxicity by Enhancing Gap Junction Activity. Biol Pharm Bull. 2022;45(4):467-476. doi: 10.1248/bpb.b21-00893.	`Click`
4	Gamma-Tocotrienol Synergistically Promotes the Anti-proliferative and Pro-apoptotic Effects of Etoposide on Breast Cancer Cell Lines. Curr Mol Pharmacol. 2022;15(7):980-986. doi: 10.2174/1874467215666220131095611.	`Click`
5	Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell Death Dis. 2018 May 1;9(5):543. doi: 10.1038/s41419-018-0575-0.	`Click`
6	Synergistic antitumor effect of β-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. Mol Med Rep. 2011 Nov-Dec;4(6):1189-93. doi: 10.3892/mmr.2011.537.	`Click`
7	Castasterone, a Plant Steroid Hormone, Affects Human Small-Cell Lung Cancer Cells and Reverses Multi-Drug Resistance. Pharmaceuticals (Basel). 2023 Jan 23;16(2):170. doi: 10.3390/ph16020170.	`Click`

No.

Title

Href

Chemosensitizing Effect of Saikosaponin B on B16F10 Melanoma Cells. Nutr Cancer. 2017 Apr;69(3):505-511. doi: 10.1080/01635581.2017.1285407.

Click

The role of oxidative stress in the cooperation of parthenolide and etoposide in HL-60 cells. Folia Med Cracov. 2020;60(4):5-17.

Click

Methylselenocysteine Potentiates Etoposide-Induced Cytotoxicity by Enhancing Gap Junction Activity. Biol Pharm Bull. 2022;45(4):467-476. doi: 10.1248/bpb.b21-00893.

Click

Gamma-Tocotrienol Synergistically Promotes the Anti-proliferative and Pro-apoptotic Effects of Etoposide on Breast Cancer Cell Lines. Curr Mol Pharmacol. 2022;15(7):980-986. doi: 10.2174/1874467215666220131095611.

Click

Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair. Cell Death Dis. 2018 May 1;9(5):543. doi: 10.1038/s41419-018-0575-0.

Click

Synergistic antitumor effect of β-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. Mol Med Rep. 2011 Nov-Dec;4(6):1189-93. doi: 10.3892/mmr.2011.537.

Click

Castasterone, a Plant Steroid Hormone, Affects Human Small-Cell Lung Cancer Cells and Reverses Multi-Drug Resistance. Pharmaceuticals (Basel). 2023 Jan 23;16(2):170. doi: 10.3390/ph16020170.

Click

Name	Etoposide
PubChem CID	36462
Molecular Weight	588.6g/mol
Synonyms	etoposide, VePesid, 33419-42-0, Toposar, trans-Etoposide, (-)-Etoposide, Lastet, Zuyeyidal, Etoposidum, Etoposido, Etoposidum [INN-Latin], VP-16, Etoposide (VP16), VP 16 (pharmaceutical), Sintopozid, Vepesid J, VP-16-213, VP 16-213, Etoposido [INN-Spanish], 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside, NK 171, CCRIS 2392, NSC-141540, DTXSID5023035, HSDB 6517, UNII-6PLQ3CP4P3, EINECS 251-509-1, 6PLQ3CP4P3, 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), EPEG, CHEBI:4911, Epipodophyllotoxin VP-16213, Etoposide (VP-16), VP 16, 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin, CHEMBL44657, Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside), Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-, Eposide, DTXCID601473876, Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside, 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside), NSC 141540, Etoposide [USAN:USP:INN:BAN:JAN], Etosid, ETOPOSIDE (IARC), ETOPOSIDE [IARC], Etoposidum (INN-Latin), Etoposido (INN-Spanish), ETOPOSIDE (MART.), ETOPOSIDE [MART.], ETOPOSIDE (USP-RS), ETOPOSIDE [USP-RS], (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, Etopophos (phosphate salt), ETOPOSIDE (EP IMPURITY), ETOPOSIDE [EP IMPURITY], ETOPOSIDE (EP MONOGRAPH), ETOPOSIDE (USP IMPURITY), ETOPOSIDE [EP MONOGRAPH], ETOPOSIDE [USP IMPURITY], ETOPOSIDE (USP MONOGRAPH), ETOPOSIDE [USP MONOGRAPH], Etopol, Prestwick 211, Demethylepipodophyllotoxin-beta-D-ethylideneglucoside, VP 16213, MFCD00869325, NSC141540, Etoposide (USAN:USP:INN:BAN:JAN), (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one, 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one, SMR000112002, VePESID (TN), 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside, Demethyl Epipodophyllotoxin Ethylidine Glucoside, Etoposide,(S), NCGC00016821-01, (5R,5aR,8aR,9S)-9-(((4aR,6R,7R,8R,8aS)-7,8-Dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, EVP, Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-, CAS-33419-42-0, Etoposide; VP-16, CPD000112002, ETOPOSIDE [INN], ETOPOSIDE [JAN], ETOPOSIDE [MI], ETOPOSIDE [HSDB], ETOPOSIDE [USAN], Prestwick3_000396, ETOPOSIDE [VANDF], 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside, ETOPOSIDE [WHO-DD], ETOPOSIDE [WHO-IP], SCHEMBL4259, BSPBio_000611, 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta(R)))-, 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4- hydroxy-3,4-dimethyloxyphenyl)furo (3',4'':6,7) naptho-(2,3-d)-1,3-dioxol-6 (5aH)-one, MLS000049957, MLS001074951, MLS001424283, MLS002153463, MLS002207239, MLS002222184, Etoposide (JP17/USP/INN), BPBio1_000673, GTPL6815, ETOPOSIDE [ORANGE BOOK], L01CB01, ETOPOSIDUM [WHO-IP LATIN], HMS2052N05, HMS2089F14, HMS2096O13, HMS2232L03, HMS3713O13, (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, EPE, EX-A1207, Tox21_110630, Tox21_302201, BDBM50127140, s1225, Etoposide - CAS 33419-42-0, AKOS007930275, BCP9000669, CCG-101165, CS-1774, DB00773, Etoposide, synthetic, >=98%, powder, NC00415, SDCCGSBI-0050405.P002, 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside, NCGC00179504-02, NCGC00255126-01, AS-35312, BE164434, Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-, Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one-, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl), (5R-(5alpha,5abeta,8aalpha,9beta(R)))-, HY-13629, ETOPOSIDE IMPURITY C (EP IMPURITY), SBI-0051910.P002, AB00438905, FT-0630571, NS00009585, EN300-97099, C01576, D00125, AB00438905-17, AB00438905-18, AB00438905_19, Q418817, SR-01000763196, SR-01000763196-3, BRD-K37798499-001-02-5, BRD-K37798499-001-05-8, BRD-K37798499-001-10-8, BRD-K37798499-001-14-0, BRD-K37798499-001-27-2, -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, Etoposide, British Pharmacopoeia (BP) Reference Standard, Z1304065033, Etoposide, European Pharmacopoeia (EP) Reference Standard, Etoposide, United States Pharmacopeia (USP) Reference Standard, 4''-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE), Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard, (5R,5AR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahy, (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one, (5R,5AR,8AR,9S)-9-((4,6-O-((1R)-ETHANE-1,1-DIYL)-.ALPHA.-D-GLUCOPYRANOSYL)OXY)-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDRO(2)BENZOFURO(5,6-F)(1,3)BENZODIOXOL-6(5AH)-ONE, (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[5,6-f][1,3]benzodioxol-8-one, (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3'',4'':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside, 121471-01-0, 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3'',4'''':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one, FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE-, 9-((4,6-O-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSYL)OXY)5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL), (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))-
Drug Type	Small molecule
Formula	C₂₉H₃₂O₁₃
SMILES	CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
InChI	1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
InChIKey	VJJPUSNTGOMMGY-MRVIYFEKSA-N
CAS Number	33419-42-0
ChEMBL ID	CHEMBL44657
ChEBI ID	CHEBI:4911
TTD ID	D0B7EB
Drug Bank ID	DB00773
KEGG ID	C01576
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Saikosaponin B1, Etoposide
Partner Name	Saikosaponin B1
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Up-regulation	Expression	H2AX	hsa3014
Gene Regulation	Down-regulation	Activity	NFKB1	hsa4790
In Vitro Model	B16-F10	Mouse melanoma	Mus musculus (Mouse)	CVCL_0159
Result	We conclude Saikosaponin B can be an attractive adjuvant for enhancing the clinical effect of cancer chemotherapy.

Pair Name	Parthenolide, Etoposide
Partner Name	Parthenolide
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Oxidative Stress
Gene Regulation	Up-regulation	Expression	GSS	hsa2937
In Vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
Result	Parthenolide did not limit the cytotoxic effect of etoposide in HL-60 cells even in the case of antagonistic interaction. If parthenolide does increase GSH levels in combination with etoposide in the normal hematopoietic cells, it could protect them against the pro-oxidative effects of this anti-cancer drug.

Pair Name	Methylselenocysteine, Etoposide
Partner Name	Methylselenocysteine
Disease Info	[ICD-11: 2C77]	Cervical cancer		Investigative
Biological Phenomena	Induction-->Gap junction activity
Gene Regulation	Up-regulation	Expression	GJB1	hsa2705
Gene Regulation	Up-regulation	Expression	GJB2	hsa2706
In Vitro Model	HeLa	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_0030
Result	We provide the novel finding that MSC increases etoposide-mediated cytotoxicity by enhancing GJ activity, due to elevated Cx expression through a GSH-dependent posttranscriptional mechanism. More generally, the study highlights potential benefit of the combination of GJ modulators and chemotherapeutic agents in anticancer treatment.

Pair Name	Gamma-Tocotrienol, Etoposide
Partner Name	Gamma-Tocotrienol
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	Our results provide evidence for the profound anti-tumorigenic effect of combined etoposide and γ-tocotrienol in the breast cancer cell lines.

Pair Name	Corylin, Etoposide
Partner Name	Corylin
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP9	hsa842
	Down-regulation	Expression	RAD51	hsa5888
In Vitro Model	Huh-7	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0336
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
In Vivo Model	A total of 4×10⁶ Huh7 cells were resuspended in 100 μl of saline with 50% Matrigel, and the suspensions were subcutaneously implanted into the left and right flank regions of the mice.
Result	Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair

Pair Name	Beta-Elemene, Etoposide
Partner Name	Beta-Elemene
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	CCND1	hsa595
	Up-regulation	Expression	CDKN1A	hsa1026
	Up-regulation	Cleavage	PARP1	hsa142
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
Result	These results suggest that the combination of β-elemene and VP-16 may be a promising therapeutic option for lung cancer.

Pair Name	Epibrassinolide, Etoposide
Partner Name	Epibrassinolide
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	CTNNB1	hsa1499
In Vitro Model	NCI-H69	Lung small cell carcinoma	Homo sapiens (Human)	CVCL_1579
In Vitro Model	VPA17	Multi-drug resistant small-cell lung cancer	Homo sapiens (Human)	N.A.
Result	Castasterone, a Plant Steroid Hormone, Affects Human Small-Cell Lung Cancer Cells and Reverses Multi-Drug Resistance